(24), who demonstrated that the Toll-like receptor 7/8 agonist resiquimod boosts the immunostimulatory capacity of human AML cells, likely correlating with the differences in immune checkpoint expression identified in our study. This evidence concerns the gene TLR7 and acute myeloid leukemia.